Table 1 Summary of previous studies

Hyman et al., 2001

Plasma: 82 AD, 271 NCI

No differences between groups (ELISA)

Weksler et al., 2002

Serum: 19 AD, 33 NCI

Decreased AD anti-Aβ levels (ELISA)

Nath et al., 2003

Serum: 16 AD, 31 NCI

Anti-Aβ higher in AD patients

Gruden et al., 2004

Serum: 17 AD, 15 NCI

Increased anti-Aβ25-35 oligomer antibodies in AD patients (ELISA)

Baril et al., 2004

Serum: 36 AD, 34 NCI

No differences between groups (ELISA)

Mruthinti et al., 2004

Plasma: 33 AD, 42 NCI

Anti-Aβ antibodies significantly (4-fold) increased in AD plasma (ELISA)

Moir et al., 2005

Plasma: 59 AD, 59 NCI

No differences for anti-Aβ monomer antibodies; decreased AD levels for anti-Aβ oligomer levels (ELISA)

Brettschneider et al., 2005

Serum: 96 AD, 30 NCI

Anti-Aβ levels decreased in AD (immunoprecipitation assay)

Jianping et al., 2006

Serum: 20 AD, 20 NCI

Decreased AD anti-Aβ levels (ELISA) and avidity

Song et al., 2007

Serum: 153 AD, 193 NCI

Decreased AD anti-Aβ levels (ELISA)

Gruden et al., 2007

Serum: 48 AD, 28 NCI

Increased anti-Aβ25-35 oligomer antibodies in AD patients (ELISA, dot blot)

Gustaw et al., 2008

Serum: 23 or 35 AD (assays performed in two laboratories), 35 NCI

Anti-Aβ levels consistently increased in AD vs. controls only after dissociation

Xu et al., 2008

Plasma: 113 AD, 205 NCI

No differences between groups (plaque immunoreactivity)

Britschgi et al., 2009

Plasma: 75 AD, 36 NCI

No differences between groups (Aβ microarrays)

Sohn et al., 2009

Serum: 136 AD, 210 NCI

Anti-Aβ decreased in AD patients (ELISA)

Gustaw-Rothenberg et al., 2010

Serum: 25 AD < 1 year, 18 NCI, 27 AD > 1 year

Anti-Aβ increased in both AD groups (ELISA) vs. NCI, before and after dissociation